Results 31 to 40 of about 49,826 (161)

Sodium-glucose transporter 2 inhibitors and their antiarrhythmic role: New insights and future perspective

Acta Marisiensis - Seria Medica
Sodium-glucose transporter 2 inhibitors have been identified as pleiotropic pharmacological agents with demonstrated efficacy in a wide range of pathologies.
Prația-Aron Diana-Ioana, Cozac Dan-Alexandru, Scridon Alina   +2 more
doaj   +1 more source

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors

Biomolecules, 2022
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is)
Francesca Romana Prandi, Lucy Barone, Dalgisio Lecis, Martina Belli, Domenico Sergi, Marialucia Milite, Stamatios Lerakis, Francesco Romeo, Francesco Barillà   +8 more
doaj   +1 more source

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure

Российский кардиологический журнал, 2021
The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes.
E. V. Kovalenko, M. V. Lozhkina, G. G. Arabidze, V. G. Kryakushkin   +3 more
doaj   +1 more source

The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes

Nature Communications
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu, Khai-Chi Hu, Mei-Yuan Liu, Yu-Jou Wu, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Kuang-Ming Liao, Chih-Cheng Lai   +11 more
doaj   +1 more source

Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis

Journal of Obesity & Metabolic Syndrome, 2021
Background : We aimed to evaluate the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for managing obesity in non-diabetic overweight or obese patients.
Yun Kyung Cho, Ye-Jee Kim, Chang Hee Jung   +2 more
doaj   +1 more source

SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review

Revista Portuguesa de Nefrologia e Hipertensão, 2023
Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown positive renal outcomes in diabetic patients. There is also emerging evidence in non-diabetic patients.
Mariana Silva de Sousa, Cristiana Maia de Almeida, Natália Marchão, Iolanda Godinho, José António Lopes, Joana Gameiro   +5 more
doaj   +1 more source

Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control

Indian Journal of Endocrinology and Metabolism, 2019
Type 2 diabetes mellitus (T2DM) is a family of metabolic disorders characterized by hyperglycemia as a consequence of abnormalities in insulin secretion and insulin sensitivity. It affects hundreds of millions of people worldwide and leads to increased morbidity, compromised quality of life, higher mortality sodium glucose co-transporter 2 (SGLT2 ...
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal   +3 more
openaire   +3 more sources

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Drugs in Context, 2014
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj   +1 more source

Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials

SAGE Open Medicine
Introduction: Polycystic ovary syndrome is a common chronic condition characterized by insulin resistance and hyperandrogenism, leading to significant health risks and impaired quality of life.
Houcem Elomma Mrabet, Houda Ben Salem, Taieb Ach, Asma Ben Abdelkarim, Wafa Alaya   +4 more
doaj   +1 more source

A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors

CPT: Pharmacometrics & Systems Pharmacology, 2023
Type 2 diabetes mellitus (T2DM) agent sodium‐glucose co‐transporter 2 (SGLT2) inhibitors show special benefits in reducing body weight and heart failure risks.
Xueting Yao, Jiawei Zhou, Ling Song, Yupeng Ren, Pei Hu, Dongyang Liu   +5 more
doaj   +1 more source